<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39330021</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1718-7729</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Current oncology (Toronto, Ont.)</Title><ISOAbbreviation>Curr Oncol</ISOAbbreviation></Journal><ArticleTitle>COVID-19 and Cancer Care: A Review and Practical Guide to Caring for Cancer Patients in the Era of COVID-19.</ArticleTitle><Pagination><StartPage>5330</StartPage><EndPage>5343</EndPage><MedlinePgn>5330-5343</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/curroncol31090393</ELocationID><Abstract><AbstractText>COVID-19, a novel infectious disease caused by the emergence of the SARS-CoV-2 virus in 2020, has had a profound impact on healthcare, both at the individual and population level. The impact at the population level was felt most acutely during the emergency phase of the pandemic, with hospital capacity issues leading to widespread disruptions and delays in the delivery of healthcare services such as screening programs and elective surgeries. While hospitals are no longer being acutely overwhelmed by COVID-19 patients, the impact of the virus on vulnerable patient populations such as cancer patients continues to be of ongoing consequence. Cancer patients remain at high risk of hospitalization, ICU admission, and death due to COVID-19, even in the era of vaccination. Infection prevention and risk mitigation strategies such air quality control, masking, testing, vaccination, and treatment should therefore be integrated into the usual care and counseling of cancer patients moving forward to avoid preventable morbidity and mortality from this infection and ensure the safety of this vulnerable cohort as they navigate their cancer diagnosis and treatment in the era of COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Claveau</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC H3A 0G4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahmood</LastName><ForeName>Farhan</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6036-1682</Identifier><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC H3A 0G4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amir</LastName><ForeName>Baraa</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwan</LastName><ForeName>Jennifer Jing Wah</ForeName><Initials>JJW</Initials><AffiliationInfo><Affiliation>Independent Researcher, Burlington, ON L7N 3V2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9745-3625</Identifier><AffiliationInfo><Affiliation>Independent Researcher, Toronto, ON M6P 3X9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vipond</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iannattone</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC H3A 0G4, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Curr Oncol</MedlineTA><NlmUniqueID>9502503</NlmUniqueID><ISSNLinking>1198-0052</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cancer care</Keyword><Keyword MajorTopicYN="N">infection prevention</Keyword></KeywordList><CoiStatement>Cheryl White and Joe Vipond are founders and volunteer board members of the Canadian Covid Society (CCS), and Cheryl White is a founder and member of Community Access to Ventilation Information (CAVI). Both are not-for-profit organizations and neither author receives any form of financial compensation for their volunteer work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39330021</ArticleId><ArticleId IdType="pmc">PMC11431468</ArticleId><ArticleId IdType="doi">10.3390/curroncol31090393</ArticleId><ArticleId IdType="pii">curroncol31090393</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peacock H.M., Tambuyzer T., Verdoodt F., Calay F., Poirel H.A., De Schutter H., Francart J., Van Damme N., Van Eycken L. Decline and Incomplete Recovery in Cancer Diagnoses during the COVID-19 Pandemic in Belgium: A Year-Long, Population-Level Analysis. ESMO Open. 2021;6:100197. doi: 10.1016/j.esmoop.2021.100197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esmoop.2021.100197</ArticleId><ArticleId IdType="pmc">PMC8411068</ArticleId><ArticleId IdType="pubmed">34474811</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinmohamed A.G., Visser O., Verhoeven R.H.A., Louwman M.W.J., van Nederveen F.H., Willems S.M., Merkx M.A.W., Lemmens V.E.P.P., Nagtegaal I.D., Siesling S. Fewer Cancer Diagnoses during the Covid-19 Epidemic in the Netherlands. Lancet Oncol. 2020;21:750–751. doi: 10.1016/S1470-2045(20)30265-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30265-5</ArticleId><ArticleId IdType="pmc">PMC7252180</ArticleId><ArticleId IdType="pubmed">32359403</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano A., Maeta A., Takaoka Y., Saeki K., Hamada M., Hiraguchi Y., Kawakami T., Okafuji I., Takemura Y., Takahashi K., et al. Parents’ Fears About Hospital Visits and Trait Anxiety in the COVID-19 Pandemic. Healthcare. 2023;11:1080. doi: 10.3390/healthcare11081080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare11081080</ArticleId><ArticleId IdType="pmc">PMC10137802</ArticleId><ArticleId IdType="pubmed">37107913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaya Y., Bostan S., Kaya A., Karaman Ö., Karataş A., Dereli S. Effect of COVID-19 Pandemic on Anxiety Depression and Intention to Go to Hospital in Chronic Patients. Int. J. Clin. Pract. 2021;75:e14219. doi: 10.1111/ijcp.14219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14219</ArticleId><ArticleId IdType="pmc">PMC8250107</ArticleId><ArticleId IdType="pubmed">33848382</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas L., Loftus R. The Forgotten “C”? The Impact of COVID-19 on Cancer Care.  [(accessed on 7 June 2024)].  Available online:  https://www.macmillan.org.uk/_images/forgotten-c-impact-of-covid-19-on-cancer-care_tcm9-359174.pdf.</Citation></Reference><Reference><Citation>Price S.T., Mainous A.G., Rooks B.J. Survey of Cancer Screening Practices and Telehealth Services Among Primary Care Physicians during the COVID-19 Pandemic. Prev. Med. Rep. 2022;27:101769. doi: 10.1016/j.pmedr.2022.101769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmedr.2022.101769</ArticleId><ArticleId IdType="pmc">PMC8928753</ArticleId><ArticleId IdType="pubmed">35313453</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Puttelaar R., Lansdorp-Vogelaar I., Hahn A.I., Rutter C.M., Levin T.R., Zauber A.G., Meester R.G.S. Impact and Recovery from COVID-19–Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis. Cancer Epidemiol. Biomark. Prev. 2023;32:22–29. doi: 10.1158/1055-9965.EPI-22-0544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-22-0544</ArticleId><ArticleId IdType="pmc">PMC9827109</ArticleId><ArticleId IdType="pubmed">36215205</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters S., Karin K., Brandt J., Lordick F., Pentheroudakis G., Curigliano G., Soo R., Bramley C., Vyas M., Jezdic S., et al.  Cancer Care during the COVID-19 Pandemic: An ESMO Guide for Patients.  [(accessed on 7 June 2024)].  Available online:  https://www.esmo.org/for-patients/cancer-care-during-the-covid-19-pandemic.</Citation></Reference><Reference><Citation>Bartlett N., Dickson-Watts K., Fiorese B., Budd A., Meere D. Cancer Screening and COVID-19 in Australia.  [(accessed on 7 June 2024)]; Available online:  https://www.aihw.gov.au/reports/cancer-screening/cancer-screening-and-covid-19-in-australia-inbrief/contents/summary.</Citation></Reference><Reference><Citation>Cancino R.S., Su Z., Mesa R., Tomlinson G.E., Wang J. The Impact of COVID-19 on Cancer Screening: Challenges and Opportunities. JMIR Cancer. 2020;6:e21697. doi: 10.2196/21697.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/21697</ArticleId><ArticleId IdType="pmc">PMC7599065</ArticleId><ArticleId IdType="pubmed">33027039</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker M.J., Meggetto O., Gao J., Espino-Hernández G., Jembere N., Bravo C.A., Rey M., Aslam U., Sheppard A.J., Lofters A.K., et al. Measuring the Impact of the COVID-19 Pandemic on Organized Cancer Screening and Diagnostic Follow-Up Care in Ontario, Canada: A Provincial, Population-Based Study. Prev. Med. 2021;151:106586. doi: 10.1016/j.ypmed.2021.106586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2021.106586</ArticleId><ArticleId IdType="pmc">PMC9755643</ArticleId><ArticleId IdType="pubmed">34217413</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong J.H., Mainprize J.G., Yaffe M.J., Ruan Y., Poirier A.E., Coldman A., Nadeau C., Iragorri N., Hilsden R.J., Brenner D.R. The Impact of Episodic Screening Interruption: COVID-19 and Population-Based Cancer Screening in Canada. J. Med. Screen. 2021;28:100–107. doi: 10.1177/0969141320974711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0969141320974711</ArticleId><ArticleId IdType="pmc">PMC7691762</ArticleId><ArticleId IdType="pubmed">33241760</ArticleId></ArticleIdList></Reference><Reference><Citation>Burus T., Lei F., Huang B., Christian W.J., Hull P.C., Ellis A.R., Slavova S., Tucker T.C., Lang Kuhs K.A. Undiagnosed Cancer Cases in the US during the First 10 Months of the COVID-19 Pandemic. JAMA Oncol. 2024;10:500–507. doi: 10.1001/jamaoncol.2023.6969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2023.6969</ArticleId><ArticleId IdType="pmc">PMC10884945</ArticleId><ArticleId IdType="pubmed">38386344</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharpless N.E. COVID-19 and Cancer. Science. 2020;368:1290. doi: 10.1126/science.abd3377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd3377</ArticleId><ArticleId IdType="pubmed">32554570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali J.K., Riches J.C. The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials. Cancers. 2021;13:5924. doi: 10.3390/cancers13235924.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13235924</ArticleId><ArticleId IdType="pmc">PMC8656780</ArticleId><ArticleId IdType="pubmed">34885038</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg D.G., Soylu T., Hoffman C.F., Kishton R.E., Cronholm P.F. ‘Anxiety, COVID, Burnout and Now Depression’: A Qualitative Study of Primary Care Clinicians’ Perceptions of Burnout. J. Gen. Intern. Med. 2024;39:1317–1323. doi: 10.1007/s11606-023-08536-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-023-08536-2</ArticleId><ArticleId IdType="pmc">PMC11169157</ArticleId><ArticleId IdType="pubmed">38010463</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotenstein L.S., Brown R., Sinsky C., Linzer M. The Association of Work Overload with Burnout and Intent to Leave the Job Across the Healthcare Workforce during COVID-19. J. Gen. Intern. Med. 2023;38:1920–1927. doi: 10.1007/s11606-023-08153-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-023-08153-z</ArticleId><ArticleId IdType="pmc">PMC10035977</ArticleId><ArticleId IdType="pubmed">36959522</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick A., Pryor R. COVID-19, Burnout, and Healthcare-Associated Infections: A Focus on Wellness as a Top Safety Priority. Antimicrob. Steward. Healthc. Epidemiol. 2023;3:e155. doi: 10.1017/ash.2023.191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2023.191</ArticleId><ArticleId IdType="pmc">PMC10523533</ArticleId><ArticleId IdType="pubmed">37771745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonds de Recherche du Québec  1st Canadian Symposium on Long COVID: Research Excellence as a Vehicle for Solutions.  [(accessed on 7 June 2024)].  Available online:  https://frq.gouv.qc.ca/en/event/1st-canadian-symposium-on-long-covid-research-excellence-as-a-vehicle-for-solutions/</Citation></Reference><Reference><Citation>Galvin G. Nearly 1 in 5 Health Care Workers Have Quit Their Jobs during the Pandemic; Volume 1.  [(accessed on 7 June 2024)].  Available online:  https://thepcc.org/2022/01/07/nearly-1-5-health-care-workers-have-quit-their-jobs-during-pandemic.</Citation></Reference><Reference><Citation>COVID Surg Collaborative Elective Surgery Cancellations Due to the COVID-19 Pandemic: Global Predictive Modelling to Inform Surgical Recovery Plans. Br. J. Surg. 2020;107:1440–1449. doi: 10.1002/bjs.11746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.11746</ArticleId><ArticleId IdType="pmc">PMC7272903</ArticleId><ArticleId IdType="pubmed">32395848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory T.A., Knight S.R., Aaroe A.E., Highsmith K.N., Janatpour Z.C., O’Brien B.J., Majd N.K., Loghin M.E., Patel C.B., Weathers S.-P., et al. Accelerated Tumor Progression After COVID-19 Infection in Patients with Glioblastoma: A Retrospective Case–Control Study. Neurooncol. Pract. 2024;11:npae029. doi: 10.1093/nop/npae029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nop/npae029</ArticleId><ArticleId IdType="pmc">PMC11241387</ArticleId><ArticleId IdType="pubmed">39006516</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker S., Jonigk D., Luft A., Dübbel L., Werlein C., Malik E., Schild-Suhren M. COVID-19 Can Lead to Rapid Progression of Cervical Intraepithelial Neoplasia by Dysregulating the Immune System: A Hypothesis. J. Reprod. Immunol. 2022;154:103763. doi: 10.1016/j.jri.2022.103763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jri.2022.103763</ArticleId><ArticleId IdType="pmc">PMC9645588</ArticleId><ArticleId IdType="pubmed">36399874</ArticleId></ArticleIdList></Reference><Reference><Citation>ElGohary G.M., Hashmi S., Styczynski J., Kharfan-Dabaja M.A., Alblooshi R.M., de la Cámara R., Mohmed S., Alshaibani A., Cesaro S., Abd El-Aziz N., et al. The Risk and Prognosis of COVID-19 Infection in Cancer Patients: A Systematic Review and Meta-analysis. Hematol. Oncol. Stem Cell Ther. 2022;15:45–53. doi: 10.1016/j.hemonc.2020.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hemonc.2020.07.005</ArticleId><ArticleId IdType="pmc">PMC7390725</ArticleId><ArticleId IdType="pubmed">32745466</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakoulis V.G., Papoutsi E., Siempos I.I. Effect of Cancer on Clinical Outcomes of Patients with COVID-19: A Meta-analysis of Patient Data. JCO Glob. Oncol. 2020;6:799–808. doi: 10.1200/GO.20.00225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/GO.20.00225</ArticleId><ArticleId IdType="pmc">PMC7328119</ArticleId><ArticleId IdType="pubmed">32511066</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S., Zhuang Q., Chiang J., Tan S.H., Chua G.W.Y., Xie C., Chua M.L.K., Soon Y.Y., Yang V.S. Impact of Cancer Diagnoses on the Outcomes of Patients with COVID-19: A Systematic Review and Meta-analysis. BMJ Open. 2022;12:e044661. doi: 10.1136/bmjopen-2020-044661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-044661</ArticleId><ArticleId IdType="pmc">PMC8822543</ArticleId><ArticleId IdType="pubmed">35131810</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W., Guan W., Chen R., Wang W., Li J., Xu K., Li C., Ai Q., Lu W., Liang H., et al. Cancer Patients in SARS-CoV-2 Infection: A Nationwide Analysis in China. Lancet Oncol. 2020;21:335–337. doi: 10.1016/S1470-2045(20)30096-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30096-6</ArticleId><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.-J., Liang W.-H., Zhao Y., Liang H.-R., Chen Z.-S., Li Y.-M., Liu X.-Q., Chen R.-C., Tang C.-L., Wang T., et al. Comorbidity and Its Impact on 1590 Patients with COVID-19 in China: A Nationwide Analysis. Eur. Respir. J. 2020;55:2000547. doi: 10.1183/13993003.00547-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00547-2020</ArticleId><ArticleId IdType="pmc">PMC7098485</ArticleId><ArticleId IdType="pubmed">32217650</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman V., Hughes S., Carle C., Campbell D., Egger S., Hui H., Yap S., Deandrea S., Caruana M., Onyeka T.C., et al. Are Patients with Cancer at Higher Risk of COVID-19-Related Death? A Systematic Review and Critical Appraisal of the Early Evidence. J. Cancer Policy. 2022;33:100340. doi: 10.1016/j.jcpo.2022.100340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcpo.2022.100340</ArticleId><ArticleId IdType="pmc">PMC9169424</ArticleId><ArticleId IdType="pubmed">35680113</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg J., Hughes S., Hui H., Allsop M.J., Egger S., David M., Caruana M., Coxeter P., Carle C., Onyeka T., et al. Risk of COVID-19 Death for People with a Pre-existing Cancer Diagnosis Prior to COVID-19-Vaccination: A Systematic Review and Meta-analysis. Int. J. Cancer. 2024;154:1394–1412. doi: 10.1002/ijc.34798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.34798</ArticleId><ArticleId IdType="pmc">PMC10922788</ArticleId><ArticleId IdType="pubmed">38083979</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy N., Vegivinti C.T.R., Mehta M., Thurnham J., Mebane A., Pederson J.M., Tarchand R., Shivakumar J., Olaniran P., Gadodia R., et al. Mortality of COVID-19 in Patients with Hematological Malignancies Versus Solid Tumors: A Systematic Literature Review and Meta-analysis. Clin. Exp. Med. 2023;23:1945–1959. doi: 10.1007/s10238-023-01004-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-023-01004-5</ArticleId><ArticleId IdType="pmc">PMC9933827</ArticleId><ArticleId IdType="pubmed">36795239</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Yang D., Chen X., Sun Z., Zou Y., Chen C., Sun S. The Effect of Anticancer Treatment on Cancer Patients with COVID-19: A Systematic Review and Meta-analysis. Cancer Med. 2021;10:1043–1056. doi: 10.1002/cam4.3692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3692</ArticleId><ArticleId IdType="pmc">PMC7897967</ArticleId><ArticleId IdType="pubmed">33381923</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao C., Gan X., Hu X., Su Y., Zhang Y., Peng X. Association of Active Immunotherapy with Outcomes in Cancer Patients with COVID-19: A Systematic Review and Meta-analysis. Aging. 2022;14:2062–2080. doi: 10.18632/aging.203945.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.203945</ArticleId><ArticleId IdType="pmc">PMC8954969</ArticleId><ArticleId IdType="pubmed">35271463</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus G., Budiman R.A., Rinaldi I. Does Immune Checkpoint Inhibitor Increase the Risks of Poor Outcomes in COVID-19-Infected Cancer Patients? A Systematic Review and Meta-analysis. Cancer Immunol. Immunother. 2022;71:373–386. doi: 10.1007/s00262-021-02990-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-021-02990-9</ArticleId><ArticleId IdType="pmc">PMC8233621</ArticleId><ArticleId IdType="pubmed">34173850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz J.I., Lopez-Olivo M.A., Geng Y., Suarez-Almazor M.E. COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review. J. Immunother. Precis Oncol. 2023;6:103–110. doi: 10.36401/JIPO-22-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.36401/JIPO-22-24</ArticleId><ArticleId IdType="pmc">PMC10195019</ArticleId><ArticleId IdType="pubmed">37214207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim Y.J., Khan U., Karpha I., Ross A., Saif M., Remberger M., Kalakonda N., Pettitt A.R., Floisand Y. COVID-19 Outcomes in Haematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis. EJHaem. 2022;3:862–872. doi: 10.1002/jha2.465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jha2.465</ArticleId><ArticleId IdType="pmc">PMC9350043</ArticleId><ArticleId IdType="pubmed">35941880</ArticleId></ArticleIdList></Reference><Reference><Citation>van Marcke C., Honoré N., van der Elst A., Beyaert S., Derouane F., Dumont C., Aboubakar Nana F., Baurain J.F., Borbath I., Collard P., et al. Safety of Systemic Anti-cancer Treatment in Oncology Patients with Non-severe COVID-19: A Cohort Study. BMC Cancer. 2021;21:578. doi: 10.1186/s12885-021-08349-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-021-08349-8</ArticleId><ArticleId IdType="pmc">PMC8134961</ArticleId><ArticleId IdType="pubmed">34016086</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortellini A., Salazar R., Gennari A., Aguilar-Company J., Bower M., Bertuzzi A., Brunet J., Lambertini M., Maluquer C., Pedrazzoli P., et al. Persistence of Long-Term COVID-19 Sequelae in Patients with Cancer: An Analysis from the OnCovid Registry. Eur. J. Cancer. 2022;170:10–16. doi: 10.1016/j.ejca.2022.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2022.03.019</ArticleId><ArticleId IdType="pmc">PMC9040509</ArticleId><ArticleId IdType="pubmed">35576848</ArticleId></ArticleIdList></Reference><Reference><Citation>Monroy-Iglesias M.J., Tremble K., Russell B., Moss C., Dolly S., Sita-Lumsden A., Cortellini A., Pinato D.J., Rigg A., Karagiannis S.N., et al. Long-Term Effects of COVID-19 on Cancer Patients: The Experience from Guy’s Cancer Centre. Future Oncol. 2022;18:3585–3594. doi: 10.2217/fon-2022-0088.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2022-0088</ArticleId><ArticleId IdType="pubmed">36172860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna A., Albi G., Figini S., Basile S., Sacchi P., Bruno R., Pedrazzoli P. Long-COVID in Patients with Cancer Previously Treated with Early Anti-SARS-CoV-2 Therapies in an Out-of-Hospital Setting: A Single-Center Experience. Cancers. 2023;15:1269. doi: 10.3390/cancers15041269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15041269</ArticleId><ArticleId IdType="pmc">PMC9953958</ArticleId><ArticleId IdType="pubmed">36831611</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagher H., Chaftari A.-M., Subbiah I.M., Malek A.E., Jiang Y., Lamie P., Granwehr B., John T., Yepez E., Borjan J., et al. Long COVID in Cancer Patients: Preponderance of Symptoms in Majority of Patients over Long Time Period. eLife. 2023;12:e81182. doi: 10.7554/eLife.81182.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.81182</ArticleId><ArticleId IdType="pmc">PMC9977271</ArticleId><ArticleId IdType="pubmed">36748905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehmsen S., Asmussen A., Jeppesen S.S., Nilsson A.C., Østerlev S., Vestergaard H., Justesen U.S., Johansen I.S., Frederiksen H., Ditzel H.J. Antibody and T Cell Immune Responses Following mRNA COVID-19 Vaccination in Patients with Cancer. Cancer Cell. 2021;39:1034–1036. doi: 10.1016/j.ccell.2021.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2021.07.016</ArticleId><ArticleId IdType="pmc">PMC8313483</ArticleId><ArticleId IdType="pubmed">34348121</ArticleId></ArticleIdList></Reference><Reference><Citation>Shem-Tov N., Yerushalmi R., Danylesko I., Litachevsky V., Levy I., Olmer L., Lusitg Y., Avigdor A., Nagler A., Shimoni A., et al. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Haematopoietic Stem Cell Transplantation Recipients. Br. J. Haematol. 2022;196:884–891. doi: 10.1111/bjh.17918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17918</ArticleId><ArticleId IdType="pmc">PMC8652777</ArticleId><ArticleId IdType="pubmed">34713441</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakal B., Abedin S., Fenske T., Chhabra S., Ledeboer N., Hari P., Hamadani M. Response to SARS-CoV-2 Vaccination in Patients After Hematopoietic Cell Transplantation and CAR T-Cell Therapy. Blood. 2021;138:1278–1281. doi: 10.1182/blood.2021012769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021012769</ArticleId><ArticleId IdType="pmc">PMC8332674</ArticleId><ArticleId IdType="pubmed">34339501</ArticleId></ArticleIdList></Reference><Reference><Citation>Passamonti F., Nicastri E., Di Rocco A., Guarini A., Ibatici A., Luminari S., Mikulska M., Visco C. Management of Patients with Lymphoma and COVID-19: Narrative Review and Evidence-Based Practical Recommendations. Hematol. Oncol. 2023;41:3–15. doi: 10.1002/hon.3086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.3086</ArticleId><ArticleId IdType="pmc">PMC9874581</ArticleId><ArticleId IdType="pubmed">36251481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ospina A.V., Brugés R., Triana I., Sánchez-Vanegas G., Barrero A., Mantilla W., Ramos P., Bernal L., Aruachán S., González M., et al. Impact of Vaccination Against COVID-19 on Patients with Cancer in ACHOC-C19 Study: Real World Evidence from One Latin American Country. J. Cancer. 2023;14:2410–2416. doi: 10.7150/jca.79969.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.79969</ArticleId><ArticleId IdType="pmc">PMC10475356</ArticleId><ArticleId IdType="pubmed">37670962</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand S.T., Vo A.D., La J., Do N.V., Fillmore N.R., Brophy M., Branch-Elliman W., Monach P.A. Severe COVID-19 in Vaccinated Adults with Hematologic Cancers in the Veterans Health Administration. JAMA Netw. Open. 2024;7:e240288. doi: 10.1001/jamanetworkopen.2024.0288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.0288</ArticleId><ArticleId IdType="pmc">PMC10891464</ArticleId><ArticleId IdType="pubmed">38393725</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID 19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health; Stapleton, NY, USA:  [(accessed on 3 June 2024)].  Available online:  https://www.covid19treatmentguidelines.nih.gov/</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouvernement du Canada  Canada.ca, 18 October 2022.  [(accessed on 3 June 2024)]; Available online:  https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/medicaments-vaccins-traitements/traitements.html.</Citation></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Simón-Campos A., et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. N. Engl. J. Med. 2022;386:1397–1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Quercia R., Di Perri G., Pein C., Bodie J., Singh R.S.P., Hendrick V., Boffito M. Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review. Infect. Dis. Ther. 2024;13:1005–1017. doi: 10.1007/s40121-024-00959-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-024-00959-6</ArticleId><ArticleId IdType="pmc">PMC11098990</ArticleId><ArticleId IdType="pubmed">38609668</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb R.L., Vaca C.E., Paredes R., Mera J., Webb B.J., Perez G., Oguchi G., Ryan P., Nielsen B.U., Brown M., et al. Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients. N. Engl. J. Med. 2022;386:305–315. doi: 10.1056/NEJMoa2116846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116846</ArticleId><ArticleId IdType="pmc">PMC8757570</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedskog C., Rodriguez L., Roychoudhury P., Huang M.-L., Jerome K.R., Hao L., Ireton R.C., Li J., Perry J.K., Han D., et al. Viral Resistance Analyses from the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1) J. Infect. Dis. 2023;228:1263–1273. doi: 10.1093/infdis/jiad270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad270</ArticleId><ArticleId IdType="pmc">PMC10629708</ArticleId><ArticleId IdType="pubmed">37466213</ArticleId></ArticleIdList></Reference><Reference><Citation>Access to Antiviral Treatments for COVID-19 in the Community, n.d.  [(accessed on 3 June 2024)].  Available online:  https://www.ontariohealth.ca/sites/ontariohealth/files/Access_to_antiviral_treatments_for_COVID-19_in_the_community.pdf.</Citation></Reference><Reference><Citation>Food and Drug Administration  Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab.  [(accessed on 3 June 2024)];2022  Available online:  https://www.fda.gov/media/145802/download.</Citation></Reference><Reference><Citation>Food and Drug Administration  Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of REGEN-COV (Casirivimab and Imdevimab)  [(accessed on 3 June 2024)];2021  Available online:  https://www.fda.gov/media/145611/download.</Citation></Reference><Reference><Citation>Food and Drug Administration  Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of Sotrovimab.  [(accessed on 3 June 2024)];2023  Available online:  https://www.fda.gov/media/149534/download.</Citation></Reference><Reference><Citation>Food and Drug Administration  Fact Sheet for Healthcare Providers: Emergency Use Authorization for Bebtelovimab.  [(accessed on 3 June 2024)];2022  Available online:  https://www.fda.gov/media/156152/download.</Citation></Reference><Reference><Citation>WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Sterne J.A.C., Murthy S., Diaz J.V., Slutsky A.S., Villar J., Angus D.C., Annane D., Azevedo L.C.P., Berwanger O., et al. Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-Analysis. JAMA. 2020;324:1330–1341. doi: 10.1001/jama.2020.17023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17023</ArticleId><ArticleId IdType="pmc">PMC7489434</ArticleId><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Yan B., Gao R., Ren J., Yang J. Effectiveness of Corticosteroids to Treat Severe COVID-19: A Systematic Review and Meta-analysis of Prospective Studies. Int. Immunopharmacol. 2021;100:108121. doi: 10.1016/j.intimp.2021.108121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108121</ArticleId><ArticleId IdType="pmc">PMC8413363</ArticleId><ArticleId IdType="pubmed">34492533</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., et al. Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med. 2021;384:693–704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Crothers K., DeFaccio R., Tate J., Alba P.R., Goetz M.B., Jones B., King J.T., Marconi V., Ohl M.E., Rentsch C.T., et al. Dexamethasone in Hospitalised COVID-19 Patients Not on Intensive Respiratory Support. Eur. Respir. J. 2022;60:2102532. doi: 10.1183/13993003.02532-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02532-2021</ArticleId><ArticleId IdType="pmc">PMC8841623</ArticleId><ArticleId IdType="pubmed">34824060</ArticleId></ArticleIdList></Reference><Reference><Citation>REMAP-CAP Investigators. Gordon A.C., Mouncey P.R., Al-Beidh F., Rowan K.M., Nichol A.D., Arabi Y.M., Annane D., Beane A., van Bentum-Puijk W., et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19. N. Engl. J. Med. 2021;384:1491–1502. doi: 10.1056/NEJMoa2100433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100433</ArticleId><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Tocilizumab in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial. Lancet. 2021;397:1637–1645. doi: 10.1016/S0140-6736(21)00676-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00676-0</ArticleId><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G., Dos Santos Moreira-Silva E.A., Silva D.C.M., Thabane L., Milagres A.C., Ferreira T.S., Dos Santos C.V.Q., de Souza Campos V.H., Nogueira A.M.R., de Almeida A.P.F.G., et al. Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalisation Among Patients with COVID-19: The TOGETHER Randomised, Platform Clinical Trial. Lancet Glob. Health. 2022;10:e42–e51. doi: 10.1016/S2214-109X(21)00448-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00448-4</ArticleId><ArticleId IdType="pmc">PMC8550952</ArticleId><ArticleId IdType="pubmed">34717820</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiersen A.M., Mattar C., Bender Ignacio R.A., Boulware D.R., Lee T.C., Hess R., Lankowski A.J., McDonald E.G., Miller J.P., Powderly W.G., et al. The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients with Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial. Open Forum Infect. Dis. 2023;10:ofad419. doi: 10.1093/ofid/ofad419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad419</ArticleId><ArticleId IdType="pmc">PMC10445518</ArticleId><ArticleId IdType="pubmed">37622035</ArticleId></ArticleIdList></Reference><Reference><Citation>Cousins K., Sano K., Lam B., Röltgen K., Bhavsar D., Singh G., McRae O., Jeong S., Aboelregal N., Ho H.-E., et al. Detection of SARS-CoV-2 Antibodies in Immunoglobulin Products. J. Allergy Clin. Immunol. Pract. 2023;11:2534–2541.e2. doi: 10.1016/j.jaip.2023.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2023.05.005</ArticleId><ArticleId IdType="pmc">PMC10176888</ArticleId><ArticleId IdType="pubmed">37182564</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam B.S., Morris R.S., Bramante C.T., Puskarich M., Zolfaghari E.J., Lotfi-Emran S., Ingraham N.E., Charles A., Odde D.J., Tignanelli C.J. mTOR Inhibition in COVID-19: A Commentary and Review of Efficacy in RNA Viruses.  [(accessed on 2 June 2024)];J. Med. Virol. 2021 93:1843–1846. doi: 10.1002/jmv.26728. Available online:  https://www.ncbi.nlm.nih.gov/pubmed/33314219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26728</ArticleId><ArticleId IdType="pmc">PMC8159020</ArticleId><ArticleId IdType="pubmed">33314219</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante C.T., Huling J.D., Tignanelli C.J., Buse J.B., Liebovitz D.M., Nicklas J.M., Cohen K., Puskarich M.A., Belani H.K., Proper J.L., et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for COVID-19. N. Engl. J. Med. 2022;387:599–610. doi: 10.1056/NEJMoa2201662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2201662</ArticleId><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>Rampant COVID Poses New Challenges in the Fifth Year of the Pandemic.  [(accessed on 22 June 2024)].  Available online:  https://www.scientificamerican.com/article/rampant-covid-poses-new-challenges-in-the-fifth-year-of-the-pandemic/</Citation></Reference><Reference><Citation>Global Technical Consultation Report on Proposed Terminology for Pathogens That Transmit Through the Air.  [(accessed on 12 June 2024)].  Available online:  https://www.who.int/publications/m/item/global-technical-consultation-report-on-proposed-terminology-for-pathogens-that-transmit-through-the-air.</Citation></Reference><Reference><Citation>Routine Practices and Additional Precautions for Preventing the Transmission of Infection in Healthcare Settings.  [(accessed on 2 June 2024)].  Available online:  https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-conditions/routine-practices-precautions-healthcare-associated-infections/routine-practices-precautions-healthcare-associated-infections-2016-FINAL-eng.pdf.</Citation></Reference><Reference><Citation>Johansson M.A., Quandelacy T.M., Kada S., Prasad P.V., Steele M., Brooks J.T., Slayton R.B., Biggerstaff M., Butler J.C. SARS-CoV-2 Transmission from People Without COVID-19 Symptoms. JAMA Netw. Open. 2021;4:e2035057. doi: 10.1001/jamanetworkopen.2020.35057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.35057</ArticleId><ArticleId IdType="pmc">PMC7791354</ArticleId><ArticleId IdType="pubmed">33410879</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian R., He Q., Pascual M. Quantifying Asymptomatic Infection and Transmission of COVID-19 in New York City Using Observed Cases, Serology, and Testing Capacity. Proc. Natl. Acad. Sci. USA. 2021;118:e2019716118. doi: 10.1073/pnas.2019716118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2019716118</ArticleId><ArticleId IdType="pmc">PMC7936345</ArticleId><ArticleId IdType="pubmed">33571106</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni A., Herbert C., Lin H., Yan Y., Pretz C., Stamegna P., Wang B., Orwig T., Wright C., Tarrant S., et al. Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection: A Prospective Cohort Study. Ann. Intern. Med. 2023;176:975–982. doi: 10.7326/M23-0385.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M23-0385</ArticleId><ArticleId IdType="pmc">PMC10321467</ArticleId><ArticleId IdType="pubmed">37399548</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu Y.-P., Green C., Hao L., Greninger A.L., Morton J.F., Sights H.A., Gale M., Drain P.K. COVID-19 Antigen Results Correlate with the Quantity of Replication-Competent SARS-CoV-2 in a Cross-Sectional Study of Ambulatory Adults during the Delta Wave. Microbiol. Spectr. 2023;11:e0006423. doi: 10.1128/spectrum.00064-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.00064-23</ArticleId><ArticleId IdType="pmc">PMC10269637</ArticleId><ArticleId IdType="pubmed">37097146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby J.E., Riedel S., Dutta S., Arnaout R., Cheng A., Ditelberg S., Hamel D.J., Chang C.A., Kanki P.J. Sars-Cov-2 Antigen Tests Predict Infectivity Based on Viral Culture: Comparison of Antigen, PCR Viral Load, and Viral Culture Testing on a Large Sample Cohort. Clin. Microbiol. Infect. 2023;29:94–100. doi: 10.1016/j.cmi.2022.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.07.010</ArticleId><ArticleId IdType="pmc">PMC9293398</ArticleId><ArticleId IdType="pubmed">35863629</ArticleId></ArticleIdList></Reference><Reference><Citation>Someone in My Home Has COVID. How do We Isolate Safely?  [(accessed on 8 June 2024)].  Available online:  https://cleanaircrew.org/someone-in-my-home-has-covid-how-do-we-isolate-safely/</Citation></Reference><Reference><Citation>Heating, Ventilation and Air Conditioning (HVAC) Systems in Buildings and COVID-19.  [(accessed on 8 June 2024)].  Available online:  https://www.publichealthontario.ca/-/media/documents/ncov/ipac/2020/09/covid-19-hvac-systems-in-buildings.pdf.</Citation></Reference><Reference><Citation>Canadian COVID-19 Hazard Index.  [(accessed on 23 June 2024)].  Available online:  https://covid19resources.ca/covid-hazard-index/</Citation></Reference><Reference><Citation>Improve Indoor Air Quality in Your Home.  [(accessed on 8 June 2024)].  Available online:  https://www.canada.ca/en/health-canada/services/air-quality/improve-indoor-air-quality-in-your-home.html.</Citation></Reference><Reference><Citation>COVID-19 Mask Use: Advice for Community Settings.  [(accessed on 8 June 2024)].  Available online:  https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks/about-non-medical-masks-face-coverings.html.</Citation></Reference><Reference><Citation>Controlling Respiratory Infectious Diseases in the Workplace.  [(accessed on 9 June 2024)].  Available online:  https://www.ccohs.ca/images/products/infographics/download/respiratory-infectious-diseases.png.</Citation></Reference><Reference><Citation>ACTION/CARE/EQUITY  Keep Masks in Healthcare.  [(accessed on 9 June 2024)].  Available online:  https://www.actioncareequity.org/</Citation></Reference><Reference><Citation>Mask Mandates Have Kept One Cancer Center Free from COVID-19. Others Have Lifted Masking Requirements Despite Patient Concerns.  [(accessed on 9 June 2024)].  Available online:  https://www.cancertherapyadvisor.com/features/mask-mandates-have-kept-one-cancer-center-free-from-covid-19-others-have-lifted-masking-requirements-despite-patient-concerns/</Citation></Reference><Reference><Citation>Klompas M., Baker M.A., Rhee C., Baden L.R. Strategic Masking to Protect Patients from All Respiratory Viral Infections. N. Engl. J. Med. 2023;389:4–6. doi: 10.1056/NEJMp2306223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2306223</ArticleId><ArticleId IdType="pubmed">37314330</ArticleId></ArticleIdList></Reference><Reference><Citation>Interim Infection Prevention and Control Recommendations for Healthcare Personnel during the Coronavirus Disease 2019 (COVID-19) Pandemic.  [(accessed on 20 August 2024)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html.</Citation></Reference><Reference><Citation>Updated Guidance for Infection Prevention and Control in Health Care Settings When COVID-19 Is Suspected or Confirmed, April 2024.  [(accessed on 20 June 2024)].  Available online:  https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/omicron-infection-prevention-control-health-care-settings-covid-19-suspected-confirmed.html.</Citation></Reference><Reference><Citation>An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)  Guidance on the Use of COVID-19 Vaccines during the Fall of 2024.  [(accessed on 20 June 2024)].  Available online:  https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/vaccines-immunization/national-advisory-committee-immunization-guidance-covid-19-vaccines-fall-2024/naci-statement-2024-05-03.pdf.</Citation></Reference><Reference><Citation>COVID-19 Vaccines: Canadian Immunization Guide.  [(accessed on 22 June 2024)].  Available online:  https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html.</Citation></Reference><Reference><Citation>Use of COVID-19 Vaccines in the U.S.  [(accessed on 20 August 2024)]; Available online:  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#table-02.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>